Table 2.
Patient and disease characteristics (n=21)
| Number of females | 11 (52%) |
| Number of males | 10 (48%) |
| Age at scanning time (median (yrs), range) | 68 (41-84) |
| WHO performance status at scanning time | |
| 1 | 13 (62%) |
| 0 | 8 (38%) |
| Location of primary tumor | |
| Esophagus or stomach | 3 (14%) |
| Small Intestine | 1 (5%) |
| Colo-rectal | 6 (29%) |
| Pancreas | 4 (19%) |
| Thymus | 1 (5%) |
| Lung | 3 (14%) |
| CUP* | 3 (14%) |
| Metastatic disease** | |
| Lymph node metastases | 11 (52%) |
| Liver metastases | 11 (52%) |
| Bone metastases | 2 (10%) |
| Brain metastases | 3 (14%) |
| Immunohistochemistry | |
| Ki67 (median (%), range) | 50 (20-100) |
| Ki67<55% | 11 (52%) |
| Ki67≥55% | 10 (48%) |
| Chromogranin A | |
| Positive | 10 (48%) |
| Focally positive | 9 (43%) |
| Negative | 2 (10%) |
| Synaptophysin positive | 21 (100%) |
| SSTR2 | |
| 3 (circumferential membranous reactivity ≥50% of tumor cells, irrespective of the presence of cytoplasmic staining) | 3 (14%) |
| 2 (membranous reactivity in <50% of tumor cells, irrespective of the presence of cytoplasmic staining) | 4 (19%) |
| 1 (pure cytoplasmic immunoreactivity, either focal or diffuse) | 10 (48%) |
| 0 (negative) | 2 (10%) |
| not done | 2 (10%) |
| SSTR5 | |
| Positive (>10% pos. cells, cytoplasmic) | 8 (38%) |
| Negative | 9 (43%) |
| Not done | 4 (19%) |
| m-TOR | |
| Positive | 3 (14%) |
| Negative | 17 (81%) |
| Not done | 1 (5%) |
| uPAR | |
| 2: stromal and circumferences and >10% positive tumor cells | 10 (48%) |
| 1: only stromal cells | 6 (29%) |
| 0: no uPAR positive cells, negative | 3 (14%) |
| not done | 2 (10%) |
*
Cancer of unknown primary.
**
Metastatic disease verified by surgery, CT or pathology.